

Newsletter #10

3 January 2022

Thanks to the PsoProtect, BSPD, and ESPD groups for their collaboration

Total number of cases reported

95

Countries (n = 14) that assessed children, n

Argentina	1	Mexico	2	Russia	6
France	52	Netherland	1	Sweden	1
Greece	1	Poland	13	Turkey	4
India	4	Portugal	2	United Kingdom	1
Italy	4	Romania	3		

Children

Girls / boys	42 / 52
Age (mean ± SD)	12.5 ± 3.7 y

Psoriasis before COVID-19

Age of onset of psoriasis (mean ± SD)	7.0 ± 4.1 y
Plaque psoriasis	61
Nail psoriasis	41
Psoriasis arthritis	7

COVID-19

Confirmed / suspected	83 / 12
N° of COVID-19 / child	
1	93
2	1
Symptoms, yes	63
Hospitalization	6
Long-Covid	2

Since COVID-19 onset, the psoriasis has

Improved	1
Worsened, with same psoriasis phenotype	12
Worsened, phenotype changed	1
Remained same	67
Psoriasis de novo	6
No information	8

Systemic medication for psoriasis at time of onset of COVID-19

Phototherapy	6	Adalimumab	12
Methotrexate	12	Etanercept	4
Acitretin	5	Ustekinumab	12
Cyclosporine	1	Risankizumab	1
Apremilast	1	Secukinumab	1

You can include children with psoriasis and COVID-19 on:

<https://docs.google.com/forms/d/e/1FAIpQLSeWcMLUXAfncx4ky8CEUILWa7veJmHb0FthGKuudaQDwbCfNQ/viewform?vc=0&c=0&w=1&flr=0>

<https://www.sfdermato.org/groupe-46-chi-psocov>